The global swine respiratory diseases treatment market is poised for significant growth, with its valuation projected to rise from USD 2.0 billion in 2022 to USD 3.6 billion by 2032. Expanding at a compound annual growth rate (CAGR) of 6.3% during the forecast period, the market’s growth reflects the increasing prevalence of respiratory diseases among swine and the rising demand for effective treatment solutions.
The dominance of Mycoplasma as a causative agent in swine respiratory diseases is a notable trend within the market. In 2021, Mycoplasma accounted for approximately 35.2% of the market share, driven by its widespread impact on swine health and the demand for targeted therapies. The focus on minimizing economic losses in swine production and improving animal welfare has intensified research and innovation in treatments for Mycoplasma-induced conditions.
Key drivers for market expansion include advancements in veterinary pharmaceuticals, increasing awareness about swine health management, and the growing demand for pork worldwide. Farmers and producers are adopting preventive measures and therapeutic solutions to curb the spread of respiratory diseases, contributing to steady growth in the treatment market. Additionally, the integration of diagnostics with treatment strategies is gaining momentum, enhancing the efficiency of disease management.
Regionally, North America and Europe lead the market due to their advanced veterinary healthcare infrastructure and large-scale swine farming operations. Meanwhile, Asia-Pacific is emerging as a key growth region, supported by increasing pork consumption, rising investments in swine health, and efforts to enhance farming productivity.
Key Takeaways:
- The global swine respiratory diseases treatment market is projected to grow from USD 2.0 billion in 2022 to USD 3.6 billion by 2032, at a CAGR of 6.3%.
- Mycoplasma, a leading causative agent, held a 35.2% market share in 2021, reflecting its significant impact on swine health.
- Growth is driven by advancements in veterinary pharmaceuticals, rising awareness about animal health, and the global demand for pork.
- North America and Europe lead the market, with Asia-Pacific emerging as a key growth region due to increasing swine production and pork consumption.
Market Dynamics
- Leading Causative Agent: Mycoplasma is the leading causative agent in this market, holding a significant share of approximately 35.2% in 2021. This highlights the impact of Mycoplasma hyopneumoniae, which is known for causing respiratory diseases in swine and leading to substantial economic losses in the industry.
- Economic Impact: The financial toll from swine respiratory diseases is considerable, with losses attributed to various pathogens, including Mycoplasma and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), significantly affecting pig production and profitability.
Key Growth Drivers
- Increasing Awareness and Prevention Measures: There is a growing awareness among swine producers regarding the importance of disease management and prevention strategies, which is driving demand for effective treatment options.
- Advancements in Veterinary Medicine: Innovations in treatment methodologies and veterinary pharmaceuticals are contributing to market growth, enabling better management of respiratory diseases in swine.
Competitive Landscape
With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.
Some of the recent developments in the swine respiratory diseases treatment market are given below:
- Merck Animal Health, also known as MSD Animal Health outside of the USA and Canada, declared in March 2022 that AROVYNTM (tulathromycin injection) and NUFLOR-S (florfenicol injectable solution), two broad-spectrum, prescription antibiotics used to treat the primary pathogens linked to swine respiratory disease (SRD), had been approved by the USA Food and Drug Administration (FDA).
- In September 2021, Invetx and Boehringer Ingelheim announced a collaboration to discover, develop, and commercialize innovative veterinary medications.
Key Companies Profiled
Zoetis; Bayer AG; Boehringer Ingelheim GmbH; Elanco Animal Health (Sub. Eli Lilly); Virbac; Norbrook; Ceva Santé Animale; Intervet Inc., (Sub. Merck & Co. Inc.); Vetoquinol SA; Bimeda Inc.; Kyoritsu Seiyaku Corporation; HIPRA; Agrilabs, Inc.; Ashish LifeSciences Ltd.; Cipla Pharmaceuticals.; Thermo Fisher Scientific Inc.; Huvepharma
A Detailed Full Report
Key Segments Covered in Swine Respiratory Diseases Treatment Market Report
By Causative Agent:
- Virus
- Mycoplasma
- Bacteria
- Others
By Treatment:
- Drugs
- Antibiotics
- Others
- Vaccines
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube